PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34521450-0	2021	Gut microbiota mediated the therapeutic efficacies and the side effects of prednisone in the treatment of MRL/lpr mice.	Prednisone	75-85	Fas (TNF receptor superfamily member 6)	Mus musculus	110-113	
34521450-4	2021	Then, this study used fecal microbiota transplantation (FMT) to transfer the gut microbiota of prednisone-treated MRL/lpr mice into the blank MRL/lpr mice to reveal whether the gut microbiota regulated by prednisone had similar therapeutic efficiency and side effects as prednisone.	Prednisone	95-105	Fas (TNF receptor superfamily member 6)	Mus musculus	118-121	
34521450-5	2021	RESULTS: The effects of prednisone on gut microbiota were dose-dependent in the treatment of MRL/lpr mice.	Prednisone	24-34	Fas (TNF receptor superfamily member 6)	Mus musculus	97-100	
34521450-6	2021	After transplantation into MRL/lpr mice, prednisone-regulated gut microbiota could alleviate lupus, which might be due to decreasing Ruminococcus and Alistipes and retaining the abundance of Lactobacillus.	Prednisone	41-51	Fas (TNF receptor superfamily member 6)	Mus musculus	31-34	
35514318-3	2022	Reduced expression of CD138 in DN T cells induced by prednisone treatment alleviated the accumulation of DN T cells in MRL/lpr mice.	Prednisone	53-63	Fas (TNF receptor superfamily member 6)	Mus musculus	123-126	
35514318-2	2022	Accumulation of CD138+ T cells in the spleen of MRL/lpr mice was significantly reduced by prednisone.	Prednisone	90-100	Fas (TNF receptor superfamily member 6)	Mus musculus	52-55	
35514318-4	2022	The frequency of CD138+ cells in CD4+ T cells of prednisone-treated MRL/lpr mice was also significantly reduced, which subsequently contributed to reduced production of anti-dsDNA antibody in the prednisone-treated MRL/lpr mice.	Prednisone	49-59	Fas (TNF receptor superfamily member 6)	Mus musculus	72-75	
35514318-4	2022	The frequency of CD138+ cells in CD4+ T cells of prednisone-treated MRL/lpr mice was also significantly reduced, which subsequently contributed to reduced production of anti-dsDNA antibody in the prednisone-treated MRL/lpr mice.	Prednisone	49-59	Fas (TNF receptor superfamily member 6)	Mus musculus	219-222	
35514318-4	2022	The frequency of CD138+ cells in CD4+ T cells of prednisone-treated MRL/lpr mice was also significantly reduced, which subsequently contributed to reduced production of anti-dsDNA antibody in the prednisone-treated MRL/lpr mice.	Prednisone	196-206	Fas (TNF receptor superfamily member 6)	Mus musculus	219-222	
32346376-9	2020	Moreover, the short-term antibiotics or FMT before onset inhibited the therapeutic efficiency of prednisone on lupus from 9 to 13 weeks old of MRL/lpr mice.	Prednisone	97-107	Fas (TNF receptor superfamily member 6)	Mus musculus	147-150	
30911862-5	2019	Treating MRL/lpr mice with prednisone (5 mg/kg) from the age of 8 weeks decreased anti-cardiolipin and anti-N-methyl-D-aspartate (NMDA) receptor antibody titres in the brain, reduced the weight of lymph nodes, and prolonged the floating latency in the forced swim test.	Prednisone	27-37	Fas (TNF receptor superfamily member 6)	Mus musculus	13-16	
31786803-0	2020	Analysis of brain metabolites by gas chromatography-mass spectrometry reveals the risk-benefit concerns of prednisone in MRL/lpr lupus mice.	Prednisone	107-117	Fas (TNF receptor superfamily member 6)	Mus musculus	125-128	
31118928-0	2019	Alterations of the Gut Microbiota Associated With Promoting Efficacy of Prednisone by Bromofuranone in MRL/lpr Mice.	Prednisone	72-82	Fas (TNF receptor superfamily member 6)	Mus musculus	107-110